This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jan 6, 2025
•
11 min read
Regeneron acquires Oxular and gets hands on novel ocular drug delivery tech, BMS's Opdivo lands new approval for subcutaneous version, Roche in-licenses Innovent ADC in up to $1B deal, General Proximity launches with $16M to go after "undruggable" disease-linked proteins, Neumora stock collapses after navacaprant Ph3 failure in major depressive disorder + 31 more stories
Dec 20, 2024
Ottimo Pharma's CEO ready to "have some fun" with $140M Series A, BMS buys two preclinical Alzheimer's antibodies from BioArctic, KdT Ventures launches a currently unnamed rare disease start-up powered by an NGM Bio asset, US government nears shutdown as PBM reform thrown to the wayside + 31 more stories
Dec 19, 2024
12 min read
Novartis & AbbVie score a 340B win in West Virginia, FDA approves Mesoblast's allogeneic mesenchymal stromal cell therapy (a US first), Novartis and BioAge Labs partner on age-related disease drug discovery, AstraZeneca likely taking a sales hit in China amid employee investigations + 36 more stories
Dec 18, 2024
10 min read
Sandoz pays $275M to settle generic price-fixing litigation, Pfizer forecasts a more stable & upbeat 2025, Akamis Bio's $60M raise fuels oncolytic gene therapy ambitions, The Big Apple gets a CGT manufacturing hub, PBMs (unsurprisingly) fight back against PBM reform + 26 more stories
Dec 17, 2024
Novo Holdings & Catalent deal full steam ahead after FTC ok, Promise Bio launches with AI-driven precision medicine for autoimmune diseases ambitions, Candid Therapeutics signs on trio of bispecific R&D deals, Roche discontinues Ph3 gene therapy asset development + 30 more stories
Dec 16, 2024
AbbVie to acquire Nimble Therapeutics for $200M, Novavax lands $50M milestone payment related to Sanofi-partnered pediatric COVID-19 vaccine, Turn Therapeutics $75M investment to fuel advanced wound and dermatology ambitions, McKinsey agrees to $650 settlement in Purdue opioid case + 29 more stories
Dec 13, 2024
Investors sue BMS on alleged reneging on milestone payments, Novo Nordisk's Ozempic lands kidney disease-related label expansion in the EU, Expression Therapeutics has “promising” Ph1 hemophilia A gene therapy data, Keros Therapeutics stock plummets on PAH clinical trial holds due to pericardial effusion cases + 32 more stories
Dec 12, 2024
Pair of (former) biotech CEOs convicted of fraud, Candel Therapeutics stock jumps on positive viral immunotherapy Ph3 data in prostate cancer, Angitia Biopharmaceuticals $120M Series C targeting musculoskeletal disorders, Q32 Bio stock collapses on "messy" trial results + 37 more stories
Dec 11, 2024
uniQure stock skyrockets on clear(er) path to accelerated approval, BioNTech's breast cancer bispecific dreams of dethroning Keytruda, Tasca Therapeutics launches with $52M to discover novel lipid-bound protein pockets, GSK and Relation partner on fibrotic disease and osteoarthritis drug discovery + 33 more stories
Dec 10, 2024
Gotta catch'em all (hematology clinical updates) at ASH 2024, Dimension's $500M second fund at the “interfaces of life science and technology”, Citryll's €85M Series B fuels inflammatory disease ambitions, Agios' discloses liver injuries from "very safe" mitapivat + 37 more stories
Dec 9, 2024
9 min read
Novo Holdings' Catalent acquisition gets go-ahead from EU regulators, Teva & Takeda divest generics joint venture to PE firm, bluebird bio touts positive long-term sickle cell disease gene therapy data, National Resilience layoffs + 24 more stories
Dec 6, 2024
8 min read
Atlas Venture closes $450M Fund XIV focused on biotech, Protara Therapeutics positive Ph2 cell therapy data launches stock upward, Nuvig Therapeutics $161M Series B for non-immune system suppressing autoimmune therapies, Eli Lilly & Amgen both announce $1B+ facility builds + 20 more stories
